Borkowska Alina, Drozdz Wiktor, Ziółkowska-Kochan Marzena, Rybakowski Janusz
Clinical Neuropsychology Unit, Nicolaus Copernicus University, Torun, Collegium Medicum, Bydgoszcz, Poland.
Neuropsychopharmacol Hung. 2007 Oct;9(3):131-6.
We put forward a hypothesis that a therapeutic administration of mirtazapine to depressed patients, due to pharmacological profile of the drug, could enhance cognitive functions associated with prefrontal cortex activity.
The study was performed on depressed patients receiving mirtazapine for the period of 6 months. Neuropsychological assessments after 3 and 6 months of treatment were performed by the Wisconsin Card Sorting Test, N-back test, TMT and Stroop tests.
During acute depressive episode, a significant impairment on all neuropsychological tests was evident. Substantial improvement in performance has been noted after 3 and 6 months of mirtazapine treatment, and, after 6 months, a majority of the investigated patients achieved the results within the range of matched healthy control subjects. Improvement on neuropsychological tests after treatment with mirtazapine showed no correlation with the degree of amelioration of depression.
Mirtazapine may exert a favorable influence on cognitive functions associated with prefrontal cortex in depressed patients. The lack of direct correlation with improvement of depressive symptoms suggests that mirtazapine may possess specific pro-cognitive properties.
我们提出一个假设，即由于米氮平的药理特性，对抑郁症患者进行治疗性给药可能会增强与前额叶皮质活动相关的认知功能。
该研究针对接受米氮平治疗6个月的抑郁症患者进行。在治疗3个月和6个月后，通过威斯康星卡片分类测验、n-back测试、TMT和斯特鲁普测试进行神经心理学评估。
在急性抑郁发作期间，所有神经心理学测试均显示出明显的损害。在米氮平治疗3个月和6个月后，观察到表现有显著改善，并且在6个月后，大多数被调查患者的结果达到了匹配的健康对照受试者范围内。米氮平治疗后神经心理学测试的改善与抑郁症状的改善程度无关。
米氮平可能对抑郁症患者与前额叶皮质相关的认知功能产生有利影响。与抑郁症状改善缺乏直接相关性表明米氮平可能具有特定的促认知特性。
